

# MEROPENEM-VABORBACTAM VERSUS BEST AVAILABLE THERAPY FOR CARBAPENEM-RESISTANT ENTEROBACTERIACEAE INFECTIONS IN TANGO II: OUTCOMES IN PATIENTS WITH CANCER

Presented at MAD-ID  
May 9-12, 2018  
Orlando, FL

PIERLUIGI VIALE<sup>1</sup>, EVANGELOS J. GIAMARELLOS-BOURBOULIS<sup>2</sup>, ROMNEY M. HUMPHRIES<sup>3</sup>, YOAV GOLAN<sup>4</sup>, GEORGE L. DAIKOS<sup>5</sup>, JEFFREY LOUTIT<sup>7</sup>, EDWARD SPINDLER<sup>6</sup>, SHU ZHANG<sup>6</sup>, THOMAS J. WALSH<sup>8</sup>, ELIZABETH L. ALEXANDER<sup>6</sup>

1. Alma Mater Studiorum University of Bologna, Bologna, Italy; 2. National and Kapodistrian University of Athens, Medical School, Greece; 3. Accelerate Diagnostics, Los Angeles, CA, USA; 4. Tufts Medical Center, Boston, MA, USA; 5. National and Kapodistrian University of Athens, Laiko Hospital, Athens, Greece; 6. Melinta Therapeutics, Parsippany, NJ, USA; 7. Weill Cornell Medicine of Cornell University, New York, NY, USA

1-844-MELINTA  
medinfo@melinta.com

## ABSTRACT

**Background:** Patients with cancer, particularly those with hematological malignancies, are at high risk for mortality due to infections caused by carbapenem-resistant Enterobacteriaceae (CRE). Meropenem-vaborbactam (M-V) is a novel cyclic boronic acid beta-lactamase inhibitor combination developed for treatment of serious gram-negative infections, including CRE. This analysis reports outcomes among oncology patients in TANGO II, a randomised, open-label comparative trial with best available therapy (BAT) in patients with complicated urinary tract infection (cUTI), acute pyelonephritis (AP), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), bacteremia, and complicated intra-abdominal infection (cIAI), due to known or suspected CRE.

**Methods:** Eligible patients were randomised 2:1 to M-V (2g/2g every 8h) or BAT for 7 to 14 days. BAT included any of the following, alone or in combination: carbapenems, aminoglycosides, polymyxin B, colistin, tigecycline, or ceftazidime-avibactam (monotherapy only). Clinical cure was defined as complete resolution of symptoms such that no further antimicrobial therapy was required. Microbiologic cure was defined as a composite of microbial eradication or presumed eradication at respective visit. Outcomes were assessed at end of treatment (EOT) and test of cure (TOC) visits.

**Results:** 72 patients were randomised. 50 (69.4%) had a baseline pathogen. 22 (30.5%) had a prior diagnosis of malignancy (14 active diagnoses, 8 inactive-past diagnoses). 15 of these patients presented with a CRE pathogen (mCRE-MITT) and with infection types of: bacteremia (53.3%), cUTI/AP (20%), HABP/VABP (13.3%), and cIAI (13.3%). In this group, 10 (66.7%) patients were also immunocompromised. Clinical cure, microbiologic cure, and Day 28 mortality among the oncology patients in the mCRE-MITT population are shown. M-V was associated with fewer drug-related adverse events (16.7% vs. 33.3%), any serious adverse event (25.0% vs. 77.8%), and renal adverse events (8.3% vs. 22.2%) than BAT.

Outcomes in Oncology, mCRE-MITT	M-V (N = 8) n (%)	BAT (N = 7) n (%)	All (N = 15) n (%)	Difference (95% CI) <sup>1</sup>
Clinical cure at EOT	7 (87.5)	1 (14.3)	8 (53.3)	+73.2 (21.0, 96.4)
Clinical cure at TOC (EOT+7 days)	6 (75.0)	0 (0)	6 (40.0)	+75.0 (27.1, 96.8)
Microbiologic cure at TOC (EOT+7 days) <sup>2</sup>	5 (62.5)	0 (0)	5 (33.3)	+62.5 (14.3, 91.5)
All-cause mortality Day 28	1 (12.5)	4 (57.1)	5 (33.3)	-44.6 (-82.2, 10.2)

EOT, end of treatment; TOC, test of cure.  
<sup>1</sup>Exact test.  
<sup>2</sup>Microbiologic cure is a composite of microbiologic eradication and presumed eradication at TOC.

**Conclusion:** In patients with a prior diagnosis of malignancy who presented with confirmed CRE infections, treatment with M-V was associated with higher clinical and microbiologic cure rates and a lower mortality rate than BAT (mCRE-MITT population). M-V is a promising treatment option for CRE in this population.

## INTRODUCTION

- Patients with underlying malignancies, particularly hematologic malignancies, are at increased risk for carbapenem-resistant Enterobacteriaceae (CRE) infections due to factors such as: underlying immunosuppression, impaired mucocutaneous barrier mechanisms (e.g., due to mucositis), prolonged hospital stay, and empiric and/or prophylactic use of broad-spectrum antimicrobial agents.<sup>1</sup>
- Among patients with solid tumors or hematologic malignancy and CRE infections, mortality rates are extremely high – up to 60%.<sup>2</sup>
- The current best available therapy involves treatment with one or more of a limited pool of antimicrobial agents that have been associated with high levels of toxicity, potential for interaction with immunosuppressive and chemotherapeutic agents, or emergence of resistance.<sup>3-5</sup>

- Meropenem-vaborbactam (M-V) is a novel beta-lactam/beta-lactamase inhibitor combination developed for the treatment of serious gram-negative infections, including CRE.<sup>6,7</sup>
- TANGO II is a Phase 3, multi-center, open-label comparative trial of the efficacy and safety of M-V versus best available therapy (BAT) in the treatment of serious infections caused by known or suspected CRE pathogens.
- Unlike most Phase 3 studies of new antimicrobials, TANGO II included patients with underlying and active malignancy, including immunocompromised patients, patients with hematological malignancies, and hematopoietic stem cell transplant recipients.<sup>8-11</sup>

## METHODS

- Phase 3, multi-center, randomised, open-label study of adults with infections due to known or suspected CRE, including complicated urinary tract infection (cUTI), acute pyelonephritis (AP), hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP), bacteremia, or complicated intra-abdominal infection (cIAI).
- Eligible patients were randomised 2:1 to monotherapy with M-V or BAT for 7-14 days (**FIGURE 1**).
  - BAT included (alone or in combination): a carbapenem, aminoglycoside, polymyxin B, colistin, tigecycline, or (monotherapy only) ceftazidime-avibactam.

- Enrollment was stratified by infection type and geographic region.
- Key inclusion criteria: known or suspected (evidence of CRE in culture or molecular testing within past 90 days) CRE pathogen, requirement of ≥7 days IV antimicrobial therapy, confirmed cUTI/AP, HABP/VABP, bacteremia, or cIAI.
- Key exclusion criteria: receipt of more than 24 hours of potentially effective antimicrobials (unless documented clinical failure), immediate life-threatening disease, known infection due to NDM, VIM, IMP or OXA-encoded beta-lactamase.
- Efforts to reduce bias included blinded investigator (BI), blinded adjudication committee (BAC), and a source control adjudication committee (for cIAI).
- Clinical cure was defined as a complete resolution of signs/symptoms such that no further antimicrobial therapy was required and was assessed by the BI and primary investigator (PI) at two time points: end of therapy (EOT) and test of cure (TOC). In cases where the assessment by the BI and PI differed, clinical cure was adjudicated by the BAC.
- Patients with underlying malignancy included all those with the key terms “cancer” or “malignancy” reported in the medical history in TANGO II. A manual review of all patients and the qualifying key terms was then performed to ensure validity, in which one patient with a key term of “malignant melanoma removal” was removed from the population. Malignancy was determined by the PI to be either ongoing or not ongoing.
- Immunocompromised status was defined as underlying active leukemia, lymphoma, prior transplant or splenectomy on medical history; any active receipt of immunosuppressive drugs including selective immunosuppressants, calcineurin inhibitors, or high-dose systemic steroids (equivalent to ≥20 mg/day of prednisone for ≥2 weeks); or neutropenia (ANC <1000 cells/mm<sup>3</sup>) at any point during the study period.
- Difference estimates and 95% confidence intervals (CI) were obtained by Fisher’s Exact test of equality.

## RESULTS

- 72 patients with known or suspected CRE were enrolled.
  - 50/72 (69.4%) were subsequently confirmed to have a qualifying (CFU criteria, corresponding sterile source) baseline gram-negative pathogen (micro-MITT population).
  - 22/72 (30.5%) had an underlying malignancy; 18 of these were immunocompromised.
  - 70/72 (97.2%) received study drug (MITT population).
    - 43/70 (61.4%) had a qualifying CRE pathogen (mCRE-MITT population).
      - 15 had an underlying malignancy; of which 10 of these were immunocompromised.
      - The most common infection type was bacteremia (8/15 patients, 53.3%) followed by cUTI/AP (3/15 patients, 20.0%) (**TABLE 1**).

	M-V (n=8) n (%)	BAT (n=7) n (%)
<b>Underlying malignancy<sup>1</sup></b>		
Leukemia/lymphoma <sup>1</sup>	4 (50.0)	2 (28.6)
Any solid tumor <sup>1</sup>	4 (50.0)	5 (71.4)
Metastatic solid tumor <sup>1</sup>	2 (25.0)	2 (28.6)
Non-metastatic solid tumor <sup>1</sup>	2 (25.0)	3 (42.9)
Immunocompromised	6 (75.0)	4 (57.1)
<b>Infection type</b>		
cUTI/AP	2 (25.0)	1 (14.3)
cIAI	0 (0)	2 (28.6)
HABP/VABP	2 (25.0)	0 (0)
Bacteremia	4 (50.0)	4 (57.1)

**TABLE 1. Baseline Characteristics of Patients with Cancer (mCRE-MITT population)**

<sup>1</sup> Patients may have more than one malignancy reported.

- A significantly higher clinical cure rate at EOT and TOC was observed in patients with cancer who were treated with M-V compared to those treated with BAT (mCRE-MITT population). The difference in clinical cure rate at EOT was 73.2% (95% CI: 21.0% to 96.4%) and at TOC was 75.5% (95% CI: 27.1% to 96.8%) for patients treated with M-V.
- A significantly higher microbiologic cure rate at TOC (62.5%, 95% CI: 14.3% to 91.5%) was observed in patients with cancer treated with M-V (mCRE-MITT population).
- M-V treatment was associated with a significant decrease in Day 28 mortality (absolute risk reduction 44.6%, 95% CI: -82.2% to 10.2%) (**TABLE 2**).


Outcomes in Oncology, mCRE-MITT	M-V (n=8) n (%)	BAT (n=7) n (%)	All (n=15) n (%)	Difference (95% CI) <sup>1</sup>
Clinical cure at EOT	7 (87.5)	1 (14.3)	8 (53.3)	+73.2 (21.0, 96.4)
Clinical cure at TOC (EOT+7 days)	6 (75.0)	0 (0)	6 (40.0)	+75.0 (27.1, 96.8)
Microbiologic cure at TOC (EOT+7 days) <sup>2</sup>	5 (62.5)	0 (0)	5 (33.3)	+62.5 (14.3, 91.5)
Day 28 mortality	1 (12.5)	4 (57.1)	5 (33.3)	-44.6 (-82.2, 10.2)

<sup>1</sup> According to Fisher’s Exact test; <sup>2</sup> Microbiologic cure is a composite of clinical cure and microbiologic eradication.

- Among patients with cancer, M-V was associated with fewer drug-related adverse events (16.7% vs. 33.3%), serious adverse events (25.0% vs. 77.8%), and renal adverse events (8.3% vs. 22.2%) than BAT (**TABLE 3**).

Adverse Events in Oncology, Safety population	M-V (n=12) n (%)	BAT (n=9) n (%)	Total (n=21) n (%)
<b>Treatment-emergent adverse events (TEAEs)</b>			
Any	9 (75.0)	9 (100.0)	18 (85.7)
Drug-related	2 (16.7)	3 (33.3)	5 (23.8)
<b>Serious adverse events</b>			
Any	3 (25.0)	7 (77.8)	10 (47.6)
Drug-related	0 (0)	0 (0)	0 (0)
<b>Study drug discontinuation due to TEAEs</b>	1 (8.3)	2 (22.2)	3 (14.3)
<b>Study discontinuation due to TEAEs</b>	1 (8.3)	4 (44.4)	5 (23.8)
<b>Renal-related safety endpoints</b>			
Hematuria	1 (8.3)	0 (0)	1 (4.8)
Renal failure	0 (0)	1 (11.1)	1 (4.8)
Renal failure acute	1 (8.3)	1 (11.1)	2 (9.5)

**TABLE 3. Adverse Events and Safety Endpoints Among Patients With Cancer (Safety population)**



cUTI, complicated urinary tract infection; AP, acute pyelonephritis; HABP/VABP, hospital-acquired/ventilator-associated bacterial pneumonia; cIAI, complicated intra-abdominal infection; CRE, carbapenem-resistant Enterobacteriaceae; EOT, end of therapy; TOC, test of cure; LFU, last follow up.

## CONCLUSIONS

- Patients with underlying malignancies (solid tumor and leukemia/lymphoma) are at increased risk for infection and mortality due to CRE pathogens.
- Approximately one-third of patients in TANGO II with a qualifying baseline CRE pathogen (mCRE-MITT population) had a prior or ongoing malignancy.
- Treatment of patients with cancer, including those immunocompromised, with meropenem-vaborbactam was associated with a significantly higher clinical and microbiologic cure rate compared to treatment with best available therapy.
- Treatment of patients with cancer, including those immunocompromised, with meropenem-vaborbactam was associated with a 44.6% absolute risk reduction in Day 28 mortality (95% CI: -82.2% to 10.2%).
- Treatment with meropenem-vaborbactam was associated with decreased adverse events, including serious adverse events and renal-related adverse events, than BAT among patients with cancer.
- Meropenem-vaborbactam is a promising new treatment option for CRE infections in this vulnerable patient population.

## DISCLOSURES

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under Contract No.HHSO100201400002C with RempeX Pharmaceuticals, a wholly-owned subsidiary of The Medicines Company. ClinicalTrials.gov Identifier: NCT01897779. Medical writing and editorial support was provided by Health and Wellness Partners, Upper Saddle River, New Jersey, funded by Melinta Therapeutics.

## REFERENCES

- Satlin MJ, Jenkins SG, Walsh TJ. The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. *Clin Infect Dis*. 2014;58(9):1274-1283.
- Satlin MJ, Chen L, Patel G, et al. Multicenter clinical and molecular epidemiologic analysis of bacteremia due to carbapenem-resistant Enterobacteriaceae (CRE) in the CRE epicenter of the United States. *Antimicrob Agents Chemother*. 2017;61(4):e02349-16.
- Alexander E, Loutit J, Tumbarello M, et al. Carbapenem-resistant Enterobacteriaceae infections: results from a retrospective series and implications for the design of prospective clinical trials. *Open Forum Infect Dis*. 2017;4(2):ofx063.
- Falagas ME, Lourida P, Poulakos P, et al. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. *Antimicrob Agents Chemother*. 2014;58(2):654-663.
- Munoz-Priego LS, Pajuelo L, Borromeo R, et al. Clinical epidemiology of the global expansion of *Klebsiella pneumoniae* carbapenemases. *Lancet Infect Dis*. 2013;13(9):785-796.
- Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid beta-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. *J Med Chem*. 2015;58(9):3682-3692.
- Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I Randomized clinical trial. *JAMA*. 2018;319(8):788-799.
- Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomized, pathogen-directed, phase 3 study. *Lancet Infect Dis*. 2016;16(6):661-673.
- Mazuski JE, Gasinski LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. *Clin Infect Dis*. 2016;62(11):1380-1389.
- Wagenlehner FM, Umeh O, Steenberg J, et al. Ceftriaxone-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomized, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet*. 2015;385(9981):1949-1956.
- National Institutes of Health. Study of the safety, tolerability and efficacy of MK-7655+imipenem+clastin versus imipenem/clastin alone for the treatment of complicated urinary tract infection (MK-7655-003). Available at: <https://clinicaltrials.gov/ct2/show/NCT01505634>. NLM Identifier: NCT01505634. Accessed March 1, 2018.